JP2016504376A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016504376A5 JP2016504376A5 JP2015551201A JP2015551201A JP2016504376A5 JP 2016504376 A5 JP2016504376 A5 JP 2016504376A5 JP 2015551201 A JP2015551201 A JP 2015551201A JP 2015551201 A JP2015551201 A JP 2015551201A JP 2016504376 A5 JP2016504376 A5 JP 2016504376A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- optionally substituted
- compound
- inhibitor
- ligand
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 claims 19
- 150000001875 compounds Chemical class 0.000 claims 17
- 239000003446 ligand Substances 0.000 claims 8
- 239000003814 drug Substances 0.000 claims 5
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 4
- 229910052760 oxygen Inorganic materials 0.000 claims 4
- 239000000651 prodrug Substances 0.000 claims 4
- 229940002612 prodrug Drugs 0.000 claims 4
- 125000003107 substituted aryl group Chemical group 0.000 claims 4
- 125000003118 aryl group Chemical group 0.000 claims 3
- 229910052799 carbon Inorganic materials 0.000 claims 3
- 239000013078 crystal Substances 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 206010022000 influenza Diseases 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- DTXOCJGLLMAFBX-UHFFFAOYSA-N oxo-[[1-[2-[[4-(oxoazaniumylmethylidene)pyridin-1-yl]methoxy]ethoxymethyl]pyridin-4-ylidene]methyl]azanium;dichloride Chemical compound [Cl-].[Cl-].C1=CC(=C[NH+]=O)C=CN1COCCOCN1C=CC(=C[NH+]=O)C=C1 DTXOCJGLLMAFBX-UHFFFAOYSA-N 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 239000012453 solvate Substances 0.000 claims 3
- 229910052717 sulfur Inorganic materials 0.000 claims 3
- 230000003612 virological effect Effects 0.000 claims 3
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 claims 2
- 101800004538 Bradykinin Proteins 0.000 claims 2
- JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 claims 2
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 claims 2
- 102100035792 Kininogen-1 Human genes 0.000 claims 2
- 239000000867 Lipoxygenase Inhibitor Substances 0.000 claims 2
- 229940122142 Lipoxygenase inhibitor Drugs 0.000 claims 2
- 229940123424 Neuraminidase inhibitor Drugs 0.000 claims 2
- 229940123066 Polymerase inhibitor Drugs 0.000 claims 2
- 239000003888 alpha glucosidase inhibitor Substances 0.000 claims 2
- 239000003242 anti bacterial agent Substances 0.000 claims 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims 2
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 2
- 230000003115 biocidal effect Effects 0.000 claims 2
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 claims 2
- 229930003827 cannabinoid Natural products 0.000 claims 2
- 239000003557 cannabinoid Substances 0.000 claims 2
- 229940125400 channel inhibitor Drugs 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 239000002911 sialidase inhibitor Substances 0.000 claims 2
- 238000003419 tautomerization reaction Methods 0.000 claims 2
- 125000001960 7 membered carbocyclic group Chemical group 0.000 claims 1
- 241000712892 Arenaviridae Species 0.000 claims 1
- 239000004215 Carbon black (E152) Substances 0.000 claims 1
- 241000711573 Coronaviridae Species 0.000 claims 1
- 102100031780 Endonuclease Human genes 0.000 claims 1
- 108010042407 Endonucleases Proteins 0.000 claims 1
- 241000711950 Filoviridae Species 0.000 claims 1
- 241000710781 Flaviviridae Species 0.000 claims 1
- 241000700586 Herpesviridae Species 0.000 claims 1
- 241000712464 Orthomyxoviridae Species 0.000 claims 1
- 241000711504 Paramyxoviridae Species 0.000 claims 1
- 241000150350 Peribunyaviridae Species 0.000 claims 1
- 241000709664 Picornaviridae Species 0.000 claims 1
- 241000712907 Retroviridae Species 0.000 claims 1
- 241000711931 Rhabdoviridae Species 0.000 claims 1
- 241000710924 Togaviridae Species 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 238000003556 assay Methods 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 238000002866 fluorescence resonance energy transfer Methods 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 229930195733 hydrocarbon Natural products 0.000 claims 1
- 150000002430 hydrocarbons Chemical group 0.000 claims 1
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 0 CC(C)(*)N(C(*)[C@]1N=C(*)C*(*)=*)C=C(C(O)=O)C1=O Chemical compound CC(C)(*)N(C(*)[C@]1N=C(*)C*(*)=*)C=C(C(O)=O)C1=O 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361750032P | 2013-01-08 | 2013-01-08 | |
| US61/750,032 | 2013-01-08 | ||
| PCT/EP2014/050168 WO2014108408A1 (en) | 2013-01-08 | 2014-01-07 | Naphthyridinone derivatives and their use in the treatment, amelioration or prevention of a viral disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016504376A JP2016504376A (ja) | 2016-02-12 |
| JP2016504376A5 true JP2016504376A5 (en:Method) | 2017-02-16 |
Family
ID=50073147
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015551201A Pending JP2016504376A (ja) | 2013-01-08 | 2014-01-07 | ナフチリジノン誘導体及びウイルス性疾患の治療、改善又は予防におけるそれらの使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US9199987B2 (en:Method) |
| EP (1) | EP2945945B1 (en:Method) |
| JP (1) | JP2016504376A (en:Method) |
| KR (1) | KR20150103672A (en:Method) |
| CN (1) | CN104903319B (en:Method) |
| BR (1) | BR112015013414A2 (en:Method) |
| CA (1) | CA2894821A1 (en:Method) |
| ES (1) | ES2597803T3 (en:Method) |
| HK (1) | HK1211288A1 (en:Method) |
| MX (1) | MX2015008292A (en:Method) |
| RU (1) | RU2015132977A (en:Method) |
| WO (1) | WO2014108408A1 (en:Method) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ736259A (en) | 2015-04-28 | 2019-09-27 | Shionogi & Co | Substituted polycyclic pyridone derivative and prodrugs thereof |
| LT3290424T (lt) | 2015-04-28 | 2023-03-10 | Shionogi & Co., Ltd | Pakeisto policiklinio piridono dariniai ir jo provaistas |
| KR102084109B1 (ko) * | 2015-12-15 | 2020-03-03 | 시오노기세야쿠 가부시키가이샤 | 캡 의존적 엔도뉴클레아제 저해제 및 항인플루엔자 약을 조합하는 것을 특징으로 하는 인플루엔자 치료용 의약 |
| CR20190123A (es) | 2016-08-10 | 2019-04-30 | Shionogi & Co | Composiciones farmacéuticas que contienen derivados de piridona policíclicos sustituídos y profármacos de los mismos |
| JP2020176263A (ja) * | 2019-04-19 | 2020-10-29 | 住友化学株式会社 | フィルム及び農園芸用施設 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5475109A (en) | 1994-10-17 | 1995-12-12 | Merck & Co., Inc. | Dioxobutanoic acid derivatives as inhibitors of influenza endonuclease |
| US6559145B2 (en) * | 2000-07-12 | 2003-05-06 | Pharmacia & Upjohn Company | Heterocycle carboxamides as antiviral agents |
| EP1790638B1 (en) | 2004-09-15 | 2013-04-03 | Shionogi Co., Ltd. | Carbamoylpyridone derivative having hiv integrase inhibitory activity |
| US20070072831A1 (en) | 2005-05-16 | 2007-03-29 | Gilead Sciences, Inc. | Integrase inhibitor compounds |
| US20110166123A1 (en) * | 2008-01-07 | 2011-07-07 | Aardea Biosciences, Inc. | Novel compositions and methods of use |
| TWI518084B (zh) | 2009-03-26 | 2016-01-21 | 鹽野義製藥股份有限公司 | 哌喃酮與吡啶酮衍生物之製造方法 |
| JP5697163B2 (ja) | 2009-03-26 | 2015-04-08 | 塩野義製薬株式会社 | 置換された３−ヒドロキシ−４−ピリドン誘導体 |
| WO2011000566A2 (en) | 2009-06-30 | 2011-01-06 | Savira Pharmaceuticals Gmbh | Compounds and pharmaceutical compositions for the treatment of negative-sense ssrna virus infections |
| WO2011041143A1 (en) | 2009-10-01 | 2011-04-07 | Merck Sharp & Dohme Corp. | HETEROCYCLIC-FUSED PYRAZOLO[4,3-c]PYRIDIN-3-ONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS |
-
2014
- 2014-01-07 CA CA2894821A patent/CA2894821A1/en not_active Abandoned
- 2014-01-07 BR BR112015013414A patent/BR112015013414A2/pt not_active IP Right Cessation
- 2014-01-07 MX MX2015008292A patent/MX2015008292A/es unknown
- 2014-01-07 WO PCT/EP2014/050168 patent/WO2014108408A1/en not_active Ceased
- 2014-01-07 CN CN201480004147.6A patent/CN104903319B/zh not_active Expired - Fee Related
- 2014-01-07 KR KR1020157016509A patent/KR20150103672A/ko not_active Withdrawn
- 2014-01-07 ES ES14703780.8T patent/ES2597803T3/es active Active
- 2014-01-07 US US14/149,381 patent/US9199987B2/en not_active Expired - Fee Related
- 2014-01-07 JP JP2015551201A patent/JP2016504376A/ja active Pending
- 2014-01-07 EP EP14703780.8A patent/EP2945945B1/en not_active Not-in-force
- 2014-01-07 HK HK15112100.5A patent/HK1211288A1/xx unknown
- 2014-01-07 RU RU2015132977A patent/RU2015132977A/ru not_active Application Discontinuation
-
2015
- 2015-10-22 US US14/920,000 patent/US9505758B2/en not_active Expired - Fee Related
-
2016
- 2016-11-28 US US15/361,710 patent/US20170290834A1/en not_active Abandoned